Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson’s disease?
Ageing Research Reviews · 2024-11 · 101 · 102474
DOI: 10.1016/j.arr.2024.102474 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2024-11. Verfasst von Zhong-Ming Qian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co.Ltd. / 411 Hospital, Shanghai University, Shanghai, China; Institute of Translation…. Hauptthemen laut MEDLINE: Parkinson Disease, Lactoferrin, Neuroprotective Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: NSFC.
Abstract (Originalsprache)
Lactoferrin (Lf) is a multifunctional protein in the transferrin family. It is involved in many physiological functions, including the regulation of iron absorption and immune response. It also has antibacterial, antiviral, anti-inflammatory, anticancer and antioxidant capabilities under pathophysiological conditions. The mammalian lactoferrin receptor (LfR) plays a key role in mediating multiple functions of Lf. Studies have shown that Lf/LfR is abnormally expressed in the brain of Parkinson's disease, and the excessive accumulation of iron in the brain caused by the overexpression of Lf and LfR is considered to be one of the initial causes of the degeneration of dopaminergic neurons in Parkinson's disease. On the other hand, a number of recent studies have reported that Lf/LfR has a significant neuroprotective effect on Parkinson's disease. In other words, it seems paradoxical that Lf/LfR has both neurodegenerative and neuroprotective effects in Parkinson's disease. This article focuses on recent advances in the possible mechanisms of the neurodegenerative and neuroprotective effects of Lf/LfR in Parkinson's disease and discusses why Lf/LfR has a seemingly contradictory role in the development of Parkinson's disease. Based on the evidence obtained so far, we believed that Lf/LfR has a neuroprotective effect on Parkinson's disease, while as to whether the overexpressed Lf/LfR is the cause of the development of Parkinson's disease, the current evidence is insufficient and further investigation needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co.Ltd. / 411 Hospital, Shanghai University, Shanghai, China; Institute of Translational and Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong…
- Institute of Translational and Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong 226001, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040…
- Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co.Ltd. / 411 Hospital, Shanghai University, Shanghai, China; Laboratory of Drug Delivery, School of Medicine, Shanghai University, 99 Shangda Road, Shangha…
Förderung
- NSFC
Zitieren
APA
Qian, Z. M., Li, W., & Guo, Q. (2024). Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson’s disease?. Ageing Research Reviews, 101, 102474. https://doi.org/10.1016/j.arr.2024.102474
Vancouver
Qian ZM, Li W, Guo Q. Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson’s disease?. Ageing Research Reviews. 2024;101:102474. doi:10.1016/j.arr.2024.102474
BibTeX
@article{Qian2024,
author = {Qian, Zhong-Ming and Li, Wei and Guo, Qian},
title = {Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson’s disease?},
journal = {Ageing Research Reviews},
year = {2024},
volume = {101},
pages = {102474},
doi = {10.1016/j.arr.2024.102474}
}
EUVIMED